PRAC meetings in 2025 and 2026

Human medicines European public assessment report (EPAR): Ruconest, conestat alfa, Angioedemas, Hereditary, Date of authorisation: 28/10/2010, Revision: 12, Status: Authorised

CTIS newsflash - 4 August 2023

Declaration of interests: Karen Quigley

Human medicines European public assessment report (EPAR): Erelzi, etanercept, Arthritis, Psoriatic;Psoriasis;Arthritis, Juvenile Rheumatoid;Arthritis, Rheumatoid;Spondylitis, Ankylosing, Date of authorisation: 23/06/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Busilvex, busulfan, Hematopoietic Stem Cell Transplantation, Date of authorisation: 09/07/2003, Revision: 19, Status: Withdrawn

Human medicines European public assessment report (EPAR): Arikayce liposomal, amikacin, Respiratory Tract Infections, Date of authorisation: 27/10/2020, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Pifeltro, doravirine, HIV Infections, Date of authorisation: 22/11/2018, Revision: 9, Status: Authorised

EMA communication perception survey report 2022

Human medicines European public assessment report (EPAR): Delstrigo, doravirine,lamivudine,tenofovir disoproxil, HIV Infections, Date of authorisation: 22/11/2018, Revision: 11, Status: Authorised